Login to MyKarger



Facebook Login

Forgot your password?
Sign up to MyKarger

Authors, Editors, Reviewers

Manuscript Submission, Check or Review Login can be found directly on our journal pages.


Journal Overview

Institutional Login

Karger supports the identity and access management tools Shibboleth and OpenAthens for subscribing institutions.


Institutional Login

Original Paper

Calcium Dobesilate Is Protective against Inflammation and Oxidative/Nitrosative Stress in the Retina of a Type 1 Diabetic Rat Model

Voabil P.a-c · Liberal J.a,d-f · Leal E.C.a,b,d,e · Bauer J.g · Cunha-Vaz J.b · Santiago A.R.a,b,e · Ambrósio A.F.a,b,e

Author affiliations

aInstitute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, and bAssociation for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal; cNKI-AvL, Division of Immunology, Amsterdam, The Netherlands; dCenter for Neuroscience and Cell Biology (CNC) and eCNC.IBILI, University of Coimbra, Coimbra, and fEscola Superior de Saúde Dr. Lopes Dias, Instituto Politécnico de Castelo Branco, Castelo Branco, Portugal; gVifor Pharma, Meyrin/Geneva, Switzerland

Keywords: Calcium dobesilateDiabetic retinopathyInflammationCytokinesOxidative stressNitrosative stress

Related Articles for ""
Ophthalmic Res 2017;58:150-161
https://doi.org/10.1159/000478784

Do you have an account?

Forgot your password?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.


Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.


To view the fulltext, please log in
Forgot your password?

To view the pdf, please log in
Forgot your password?

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 14, 2017
Accepted: June 16, 2017
Published online: August 10, 2017
Issue release date: September 2017

Number of Print Pages: 12
Number of Figures: 7
Number of Tables: 1

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE

Abstract

Calcium dobesilate (CaD) has been prescribed to some patients in the early stages of diabetic retinopathy to delay its progression. We previously reported that the treatment of diabetic animals (4 weeks of diabetes) with CaD, during the last 10 days of diabetes, prevents blood-retinal barrier breakdown. Here, we aimed to investigate whether later treatment of diabetic rats with CaD would reverse inflammatory processes in the retina. Diabetes was induced with streptozotocin, and 6 weeks after diabetes onset, CaD (100 mg/kg/day) was administered for 2 weeks. The treatment with CaD significantly increased glial fibrillary acidic protein (GFAP) levels in the retina of nondiabetic animals (138.6 ± 12.8% of control) and enhanced the diabetes-induced increase in GFAP levels (174.8 ± 5.6% of control). In addition, CaD prevented the increase in mRNA and protein expression of tumor necrosis factor and interleukin-1β, as well as the formation of oxidized carbonyl residues and the increase in nitrotyrosine immunoreactivity, particularly in the ganglion cell layer of diabetic animals. We demonstrate that the treatment of diabetic animals with CaD can reverse the established proinflammatory processes in the retina. These beneficial effects appear to be attributed, at least partially, to the antioxidant properties of CaD.

© 2017 S. Karger AG, Basel

References

  1. Cai J, Boulton M: The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (Lond) 2002;16:242-260.
  2. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP: Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009;5:8-13.
  3. Leal EC, Santiago AR, Ambrosio AF: Old and new drug targets in diabetic retinopathy: from biochemical changes to inflammation and neurodegeneration. Curr Drug Targets CNS Neurol Disord 2005;4:421-434.
  4. Lutty GA: Effects of diabetes on the eye. Invest Ophthalmol Vis Sci 2013;54:ORSF81-ORSF87.
  5. Kern TS: Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007;2007:95103.
  6. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrosio AF, Forrester JV: Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007;48:5257-5265.
  7. Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J, Cunha-Vaz J, Ambrosio AF: Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 2010;59:2637-2645.
  8. Noda K, Nakao S, Ishida S, Ishibashi T: Leukocyte adhesion molecules in diabetic retinopathy. J Ophthalmol 2012;2012:279037.
  9. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N: Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-1444.
  10. Cui Y, Xu X, Bi H, Zhu Q, Wu J, Xia X, Qiushi R, Ho PC: Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res 2006;83:807-816.
  11. Kowluru RA, Koppolu P, Chakrabarti S, Chen S: Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res 2003;37:1169-1180.
  12. Kowluru RA: Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003;52:818-823.
  13. Zhong Q, Kowluru RA: Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011;60:1304-1313.
  14. Berthet P, Farine JC, Barras JP: Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract 1999;53:631-636.
  15. Rabe E, Jaeger KA, Bulitta M, Pannier F: Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology 2011;26:162-168.
  16. Daubresse JC, Meunier R, Dumont P: A controlled clinical trial of calcium dobesylate in the treatment of diabetic retinopathy. Diabete Metab 1977;3:27-30.
  17. Haas A, Trummer G, Eckhardt M, Schmut O, Uyguner I, Pfeiffer KP: Effect of calcium dobesilate on progression of diabetic retinopathy (in German). Klin Monatsbl Augenheilkd 1995;207:17-21.
  18. Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW; CALDIRET study group: Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009;373:1364-1371.
  19. Benarroch IS, Brodsky M, Rubinstein A, Viggiano C, Salama EA: Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res 1985;17:131-138.
  20. Javadzadeh A, Ghorbanihaghjo A, Adl FH, Andalib D, Khojasteh-Jafari H, Ghabili K: Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis 2013;19:62-68.
  21. Leite EB, Mota MC, de Abreu JR, Cunha-Vaz JG: Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol 1990;14:81-88.
  22. Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG, DX-Retinopathy Study Group: Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol 2006;244:1591-1600.
  23. Santiago AR, Gaspar JM, Baptista FI, Cristovao AJ, Santos PF, Kamphuis W, Ambrosio AF: Diabetes changes the levels of ionotropic glutamate receptors in the rat retina. Mol Vis 2009;15:1620-1630.
  24. Gaspar JM, Martins A, Cruz R, Rodrigues CM, Ambrosio AF, Santiago AR: Tauroursodeoxycholic acid protects retinal neural cells from cell death induced by prolonged exposure to elevated glucose. Neuroscience 2013;253:380-388.
  25. Abu El-Asrar AM, Meersschaert A, Dralands L, Missotten L, Geboes K: Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye (Lond) 2004;18:306-313.
  26. Rungger-Brandle E, Dosso AA, Leuenberger PM: Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000;41:1971-1980.
  27. Du Y, Smith MA, Miller CM, Kern TS: Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002;80:771-779.
  28. Beyer J, Meissner KO, Happ J, Cordes U: Effect of calcium dobesilate on permeation of plasma proteins in diabetic patients (in German). Dtsch Med Wochenschr 1980;105:1604-1608.
  29. Van Bijsterveld OP, Janssen PT: The effect of calcium dobesilate on albumin leakage of the conjunctival vessels. Curr Eye Res 1981;1:425-430.
  30. Vojnikovic B: Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res 1991;23:12-20.
  31. Zhang X: Therapeutic effects of calcium dobesilate on diabetic nephropathy mediated through reduction of expression of PAI-1. Exp Ther Med 2013;5:295-299.
  32. Eren M, Boe AE, Murphy SB, Place AT, Nagpal V, Morales-Nebreda L, Urich D, Quaggin SE, Budinger GR, Mutlu GM, Miyata T, Vaughan DE: PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci USA 2014;111:7090-7095.
  33. Michal M, Giessinger N: Effect of calcium dobesilate and its interaction with aspirin on thrombus formation in vivo. Thromb Res 1985;40:215-226.
  34. Michal M, Gotti C: Effect of calcium dobesilate on platelet function. Thromb Res 1988;51:593-605.
  35. Padilla E, Ganado P, Sanz M, Zeini M, Ruiz E, Trivino A, Ramirez AI, Salazar JJ, Ramirez JM, Rojas B, Hoz R, Tejerina T: Calcium dobesilate attenuates vascular injury and the progression of diabetic retinopathy in streptozotocin-induced diabetic rats. Diabetes Metab Res Rev 2005;21:132-142.
  36. Brunet J, Farine JC, Garay RP, Hannaert P: In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998;12:205-212.
  37. Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, Berta A, Garay RP: Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol 2001;428:277-286.
  38. Rota R, Chiavaroli C, Garay RP, Hannaert P: Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 2004;495:217-224.
  39. Lameynardie S, Chiavaroli C, Travo P, Garay RP, Pares-Herbute N: Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats. Eur J Pharmacol 2005;510:149-156.
  40. Yang W, Yu X, Zhang Q, Lu Q, Wang J, Cui W, Zheng Y, Wang X, Luo D: Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor. Exp Eye Res 2013;115:96-105.
  41. Fernandez IS, Cuevas P, Angulo J, Lopez- Navajas P, Canales-Mayordomo A, Gonzalez-Corrochano R, Lozano RM, Valverde S, Jimenez-Barbero J, Romero A, Gimenez-Gallego G: Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem 2010;285:11714-11729.
  42. Kang W, Hebert JM: Signaling pathways in reactive astrocytes, a genetic perspective. Mol Neurobiol 2011;43:147-154.
  43. Sofroniew MV: Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009;32:638-647.
  44. Adamiec-Mroczek J, Oficjalska-Mlynczak J, Misiuk-Hojlo M: Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: analysis of vitreous samples. Cytokine 2010;49:269-274.
  45. Swanson RA, Ying W, Kauppinen TM: Astrocyte influences on ischemic neuronal death. Curr Mol Med 2004;4:193-205.
  46. Lin JH, Lou N, Kang N, Takano T, Hu F, Han X, Xu Q, Lovatt D, Torres A, Willecke K, Yang J, Kang J, Nedergaard M: A central role of connexin 43 in hypoxic preconditioning. J Neurosci 2008;28:681-695.
  47. Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, Mucke L, Johnson MH, Sofroniew MV: Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 1999;23:297-308.
  48. Marz P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U: Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999;26:191-200.
  49. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV: Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004;24:2143-2155.
  50. Verardo MR, Lewis GP, Takeda M, Linberg KA, Byun J, Luna G, Wilhelmsson U, Pekny M, Chen DF, Fisher SK: Abnormal reactivity of Muller cells after retinal detachment in mice deficient in GFAP and vimentin. Invest Ophthalmol Vis Sci 2008;49:3659-3665.
  51. Gaucher D, Chiappore JA, Paques M, Simonutti M, Boitard C, Sahel JA, Massin P, Picaud S: Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res 2007;47:612-623.
  52. Ghirlanda G, Di Leo MA, Caputo S, Falsini B, Porciatti V, Marietti G, Greco AV: Detection of inner retina dysfunction by steady-state focal electroretinogram pattern and flicker in early IDDM. Diabetes 1991;40:1122-1127.
  53. Kowluru RA: Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 2001;38:179-185.
  54. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S: Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006;20:1366-1369.
  55. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, Levison SW: Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005;54:1559-1565.
  56. Kowluru RA, Odenbach S: Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 2004;45:4161-4166.
  57. Tezel G, Li LY, Patil RV, Wax MB: TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001;42:1787-1794.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 14, 2017
Accepted: June 16, 2017
Published online: August 10, 2017
Issue release date: September 2017

Number of Print Pages: 12
Number of Figures: 7
Number of Tables: 1

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2017, Vol.58, No. 3

September 2017

Article

This Article is Part of
Recommend This
TOP